Gesine van Mark
Overview
Explore the profile of Gesine van Mark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bohmann K, Burgdorf C, Zeus T, Joner M, Alvarez H, Berning K, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268296
The transcatheter aortic valve implantation (TAVI) treatment pathway is complex, leading to procedure-related delays. Dedicated TAVI coordinators can improve pathway efficiency. COORDINATE was a pilot observational prospective registry at three...
2.
van Mark G, Tittel S, Welp R, Gloyer J, Sziegoleit S, Barion R, et al.
BMJ Open Diabetes Res Care
. 2021 Jun;
9(1).
PMID: 34083247
Introduction: The aims of this study were to characterize insulin-treated individuals aged ≥75 years with type 2 diabetes using basal insulin analogs (BIA) or regular insulins (human insulin (HI)/neutral protamine...
3.
Beime B, Bramlage C, Kruger R, Deutsch C, van Mark G, Bramlage P, et al.
Blood Press Monit
. 2021 Mar;
26(4):299-304.
PMID: 33734119
Objective: Aim of this study was to validate the Microlife BP B3 AFIB/enterprise resource planning (ERP) No: BP3KT1-3 N blood pressure (BP) monitor according to the American National Standards Institute...
4.
van Mark G, Tittel S, Sziegoleit S, Putz F, Durmaz M, Bortscheller M, et al.
Ther Adv Endocrinol Metab
. 2020 Oct;
11:2042018820958296.
PMID: 33014328
Background: The clinical profile differs between old and young patients with type 2 diabetes mellitus (T2DM). We explored, based on a large real-world database, patient and disease characteristics and actual...
5.
Hartmann B, Lanzinger S, van Mark G, Wosch F, Durmaz M, Plaumann M, et al.
Acta Diabetol
. 2019 Sep;
57(2):229-236.
PMID: 31471633
Aims: Our study aimed to analyse treatment strategies after failure of initial metformin mono-therapy in adult patients with type-2 diabetes (T2DM). Methods: The DIVE and DPV databases were combined and...
6.
van Mark G, Lanzinger S, Sziegoleit S, Putz F, Durmaz M, Borscheller M, et al.
Adv Ther
. 2019 May;
36(7):1628-1641.
PMID: 31119688
Introduction: Insulin glargine 300 U/ml (U300) was registered based on the EDITION clinical trial program. The aim of this database analysis was to describe the profile of adult U300 recipients...
7.
Bramlage P, Lanzinger S, van Mark G, Hess E, Fahrner S, Heyer C, et al.
Cardiovasc Diabetol
. 2019 Mar;
18(1):33.
PMID: 30878037
Background: To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany. Methods: Using combined DPV/DIVE registry data, the analysis included patients...
8.
van Mark G, Lanzinger S, Barion R, Degenhardt M, Badis S, Noll H, et al.
Ther Adv Endocrinol Metab
. 2019 Mar;
10:2042018819830867.
PMID: 30834104
Background: An understanding of the current status of patients with type 1 diabetes mellitus (T1DM) can help to provide appropriate treatment. Methods: This was a retrospective analysis of the DIabetes...
9.
Brinkmeier-Theofanopoulou M, Tzamalis P, Wehrkamp-Richter S, Radzewitz A, Merkel M, Schymik G, et al.
BMC Cardiovasc Disord
. 2018 Apr;
18(1):71.
PMID: 29703158
Background: There is a lack of data on anticoagulation requirements during ablation of atrial fibrillation (AF). This study compares different oral anticoagulation (OAC) strategies to evaluate risk of bleeding and...